What is the apixaban dosing equivalent to therapeutic low‑molecular‑weight heparin (LMWH) and for VTE prophylaxis, and how should the dose be adjusted for patients who are elderly, have low body weight, or have impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban Dosing Equivalent to Therapeutic LMWH and VTE Prophylaxis

For VTE treatment, apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily is the therapeutic equivalent to LMWH (enoxaparin 1 mg/kg twice daily or dalteparin 200 IU/kg daily), while for VTE prophylaxis, apixaban 2.5 mg twice daily is used post-orthopedic surgery. 1

VTE Treatment Dosing

Standard Therapeutic Dosing

  • Apixaban: 10 mg orally twice daily for 7 days, then 5 mg twice daily 1
  • LMWH equivalent:
    • Enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily 2, 3
    • Dalteparin 200 IU/kg subcutaneously once daily 2, 3
    • Tinzaparin 175 IU/kg subcutaneously once daily 2

Key advantage: Apixaban requires no initial parenteral anticoagulation, unlike dabigatran or edoxaban which require 5-10 days of LMWH bridging 4

Extended/Secondary Prophylaxis (After ≥6 months of treatment)

  • Apixaban: 2.5 mg twice daily 1
  • This lower dose is specifically for recurrence prevention after completing initial treatment phase 4

VTE Prophylaxis Dosing

Post-Orthopedic Surgery

  • Apixaban: 2.5 mg twice daily starting 12-24 hours post-surgery 1
    • Hip replacement: 35 days duration
    • Knee replacement: 12 days duration
  • LMWH equivalent:
    • Enoxaparin 40 mg once daily 2
    • Dalteparin 5,000 IU once daily 2

Dose Adjustments for Special Populations

Renal Impairment

Critical consideration: Apixaban has minimal renal clearance compared to LMWH, making it advantageous in renal dysfunction 4, 5

  • CrCl <30 mL/min:

    • Apixaban: No specific dose reduction required for VTE treatment 1
    • LMWH: Enoxaparin requires dose reduction to 1 mg/kg once daily for treatment and 30 mg once daily for prophylaxis 6
    • Avoid: Rivaroxaban, edoxaban, and standard-dose LMWH are contraindicated 4
    • Consider monitoring anti-Xa levels if using dalteparin (target 0.5-1.5 IU/mL) 6
  • CrCl 30-50 mL/min:

    • Apixaban: No dose adjustment needed 1
    • LMWH: Exercise caution; some evidence supports dose reduction for enoxaparin 6

Elderly Patients (≥80 years)

  • Apixaban: Dose reduction to 2.5 mg twice daily for atrial fibrillation if ≥80 years PLUS either weight ≤60 kg OR creatinine ≥1.5 mg/dL 1
  • For VTE treatment: Standard dosing (10 mg→5 mg twice daily) is maintained regardless of age 1
  • LMWH: Use with caution, particularly tinzaparin in patients ≥70 years with renal insufficiency (avoid due to increased mortality) 6

Low Body Weight (≤60 kg)

  • Apixaban: Dose reduction to 2.5 mg twice daily for atrial fibrillation only if weight ≤60 kg PLUS either age ≥80 years OR creatinine ≥1.5 mg/dL 1
  • For VTE treatment: No dose adjustment 1
  • LMWH: Limited data; use caution with standard weight-based dosing 6

Obesity (BMI ≥40 kg/m² or weight >100 kg)

  • Apixaban: No dose adjustment; standard fixed dosing is appropriate even with BMI >40 kg/m² 7
  • LMWH:
    • Enoxaparin: Consider reduced dose of 0.8 mg/kg twice daily for BMI ≥40 kg/m² 8, 7
    • Dalteparin/tinzaparin: No dose capping for weight <140 kg 7
    • Do not monitor anti-Xa levels for dose adjustment 5, 9

Cancer-Associated VTE

For cancer-associated VTE, oral factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) are now preferred over LMWH for initial and long-term treatment. 10

  • Apixaban: Standard dosing (10 mg→5 mg twice daily) is recommended 10
  • Important caveat: For luminal GI malignancies, apixaban or LMWH may be preferred over rivaroxaban/edoxaban due to lower GI bleeding risk 10
  • Extended prophylaxis: Low-dose apixaban 2.5 mg twice daily after initial treatment shows superior safety with similar efficacy compared to full-dose 11
  • LMWH alternative: Dalteparin remains category 1 recommendation (200 IU/kg daily for 1 month, then 150 IU/kg daily) 4, 8

Common Pitfalls to Avoid

  1. Do not bridge apixaban with parenteral anticoagulation when initiating VTE treatment—it is started immediately without LMWH overlap 4, 1

  2. Do not confuse treatment doses with extended prophylaxis doses—apixaban 2.5 mg twice daily is only for extended prophylaxis after ≥6 months of treatment, not for acute VTE 1

  3. Do not automatically reduce apixaban dose in elderly or low-weight patients for VTE treatment—dose reduction criteria apply primarily to atrial fibrillation indication 1

  4. Do not use anti-Xa monitoring to guide LMWH dosing in obesity—use actual body weight-based dosing instead 5, 9

  5. Avoid tinzaparin in elderly patients (≥70 years) with renal insufficiency due to increased mortality risk 6

  6. For severe renal impairment (CrCl <30 mL/min), apixaban is preferred over LMWH due to lower renal clearance and no required dose adjustment 5, 12

References

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Guideline

cancer-associated venous thromboembolic disease, version 2.2024, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.